Gerencia de Atencion Primaria de Murcia, Murcia Health Service, Spain.
Eur J Gen Pract. 2010 Jun;16(2):92-9. doi: 10.3109/13814788.2010.481709.
To investigate the prevalence and types of potential drug interactions in primary care patients to detect risky prescriptions as an essential condition to design intervention policies leading to an improvement in patient safety.
Cross-sectional descriptive study.
Two areas in Spain comprising 715,661 inhabitants.
430,525 subjects with electronic medical records and assigned to a family doctor regularly updating them.
On a random day, 29.4% of the population was taking medication. Of these, 73.9% were at risk of suffering interactions, and these were found in 20.6% of them. The amount of interactions was higher among people with chronic conditions, the elderly, females and polymedicated patients. From the total of interactions, 55.1% belonged to the highest clinical relevance 'A' level, and 28.3% should have been avoided. The active ingredients primarily involved were hydrochlorothiazide and ibuprofen and, when focusing on those that should be avoided, omeprazole and acenocoumarol. The most frequent 'A' interaction that should be avoided was between non-conjugated excreted benzodiazepines and proton-pump inhibitors, followed by some NSAIDs and diuretics.
1 in 20 Spanish citizens is currently undergoing a potential drug interaction, including a high rate of clinically relevant ones that should be avoided. These results confirm the existence of a serious safety issue that should be approached and where all parties involved (physicians, health services, medical societies and patients) must do our bit to improve. Health services should foster the implementation of prescription alert systems linked with electronic medical records including clinical data.
调查初级保健患者中潜在药物相互作用的流行率和类型,以发现危险处方,作为制定干预政策以提高患者安全性的必要条件。
横断面描述性研究。
西班牙的两个地区,共 715661 名居民。
430525 名有电子病历并定期分配给家庭医生更新的患者。
在随机一天,29.4%的人口正在服用药物。其中,73.9%有发生相互作用的风险,其中 20.6%的患者发生了相互作用。患有慢性病、老年人、女性和多药治疗患者的相互作用数量更高。在总相互作用中,55.1%属于最高临床相关性“A”级,28.3%应该避免。主要涉及的活性成分是氢氯噻嗪和布洛芬,而当关注那些应该避免的药物时,则是奥美拉唑和醋硝香豆素。最常见的应避免的“A”类相互作用是未结合排泄的苯二氮䓬类药物和质子泵抑制剂,其次是一些非甾体抗炎药和利尿剂。
目前,1/20 的西班牙公民正在经历潜在的药物相互作用,其中包括大量应避免的具有临床相关性的相互作用。这些结果证实了存在严重的安全问题,应该加以解决,所有相关方(医生、卫生服务机构、医学协会和患者)都必须为此做出努力。卫生服务部门应促进与电子病历相关联的处方警报系统的实施,包括临床数据。